Matt Patricelli

Matt Patricelli joined Vividion in 2016 as a founding scientific member of the company’s management team. In his current role, Matt supports all early drug discovery efforts including target selection and validation, as well as the continued development and execution of Vividion’s chemical proteomics platform.

Prior to joining Vividion, Matt served as the Senior Director of Biology at Wellspring Biosciences where he led several drug discovery programs including the KRAS-G12C covalent inhibitor discovery project. From 2000-2012 Matt led the chemical proteomics platform activities at ActivX Biosciences. He was the first Scientist to join ActivX and played a key role in the development of ActivX’s platform technologies, including establishing the KiNativ platform which continues to operate as a successful commercial screening service.

Matt obtained his BSc in Biochemistry from McGill University, and PhD from The Scripps Research Institute as the first graduate student of Vividion founder Dr. Benjamin Cravatt. He is an author or co-author of more than 30 scientific publications, and 3 issued patents.